Revelation Biosciences, Inc. - Common Stock (REVB)
4.0002
-0.1998 (-4.76%)
Revelation Biosciences Inc is a biotechnology company focused on developing innovative therapies and diagnostics to address unmet medical needs, particularly in the areas of respiratory and immune-related diseases
The company leverages its proprietary platforms to explore novel treatments that may enhance immune response or provide protection against infectious agents, utilizing advanced research methodologies and clinical trials to validate its programs. By combining cutting-edge science with a commitment to improving patient care, Revelation Biosciences aims to deliver transformative solutions in the rapidly evolving healthcare landscape.
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met its primary endpoint and identified a maximum tolerated dose.
